---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-23-000007"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:07:36.593287+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record 2022 revenue of $1.94B, up 15% YoY; Q4 EPS $2.67

## Summary
- Full year total revenues $1.94B, up 15% YoY; net income $727.3M ($15.00 diluted EPS).
- Q4 revenues $491.5M, net income $132.1M ($2.67 diluted EPS).
- Tyvaso net product sales $873M for 2022, up 44% YoY driven by Tyvaso DPI launch and PH-ILD expansion.
- Treprostinil product sales grew 19% in 2022; company targets $4B revenue run rate by end of 2025.
- Unituxin sales declined 10% to $182.9M; Adcirca down 26% due to generic competition.

## SEC filing metadata
- accession: 0001082554-23-000007
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/uthr-20230222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-23-000007
- JSON: https://secwatch.observer/filing/0001082554-23-000007.json
- Plain text: https://secwatch.observer/filing/0001082554-23-000007.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported Three Months Ended December 31, 2022 results: revenue $ 491.5, net income $ 132.1, EPS $ 2.67.
  - Period: Three Months Ended December 31, 2022
  - Revenue: $ 491.5
  - Net income: $ 132.1
  - EPS: $ 2.67
  - Result: reported results
  source text: Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm
- Earnings Releases
  UNITED THERAPEUTICS Corp reported Year Ended December 31, 2022 results: revenue $ 1,936.3, net income $ 727.3, EPS $ 15.00.
  - Period: Year Ended December 31, 2022
  - Revenue: $ 1,936.3
  - Net income: $ 727.3
  - EPS: $ 15.00
  - Result: reported results
  source text: Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255423000007/0001082554-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.